Biosyngen Pte Ltd

Title: Biosyngen

URL Source: http://www.biosyngen.com/

Markdown Content:
Biosyngen

===============

Technology

Pipeline

About Us

NEWS

Careers

Contact

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

G iving P atients the B est C hance to S urvive

Biosyngen is a Global Leader in Cell Therapy.

We design cutting-edge immunotherapies aiming to provide patients the best treatment option.

LEARN MORE

Pipelines consisting of 3 proven technologies in CGT (CAR-T, TCR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more

No approved cell immunotherapy for solid tumor to date

Currently, more than half of clinical trials are focusing on blood cancer. However, the larger unmet need and challenge is Solid Tumor.

90% of all cancer patients with solid tumors

According to the global cancer data of 2021, more than 90% of newly cancer cases worldwide are solid tumor patients, significantly outnumbering patients with blood cancers.

Developing cutting-edge immunotherapies to address unmet needs in oncology

Developing first-in-class (FIC) product against solid tumors

Products in the pipeline are first-in-class (FIC) against solid tumors, focusing on unmet needs globally, well positioned to fill the gap in the market.

Pipelines consisting of 3 proven technologies in CGT (CAR-T, TCR-T, TIL) targeting Nasopharyngeal/Lung/Liver/Gastrointestinal Cancers, and more

TCR-T

CAR-T

TCR-T

Biosyngen's Differentiation · Next generation design enhancing the persistence of T cells in vivo

· High affinity/avidity/specificity against tumor specific antigen

* Biosyngen's Pipeline · BRL03: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.

LEARN MORE

TIL

Biosyngen's Differentiation · Able to be cryopreserved to address long distance transportation issue

· Does not require high dose IL-2 infusion

* Biosyngen's Pipeline · BST02: US (IND), CN (IND)，Ongoing Phase I clinical in China/U.S.

LEARN MORE

CAR-T

Biosyngen's Differentiation · In-human data showing clinical efficacy

· Unique target/FIC

· Enhanced safety profile

* Biosyngen's Pipeline · BRG01: Ongoing Phase II clinical trials in China/U.S.

· BGT007: Dual CAR-T, IIT in progress

· ALLO-CEL: In-human by 2024

LEARN MORE

Established proprietary technology platforms for R&D translation &

immunotherapy drug development against solid tumors

M-CEL

Automated and intelligent cell manufacturing platform

M-CEL

Automated and intelligent cell manufacturing platform

· Improved production cycle time of CAR-T/TCR-T product to 10-days.

·Manufactured in GMP facility in compliance to FDA and CDE requirements. LEARN MORE

* SUPER-T

T cell safety optimization platform

SUPER-T

T cell safety optimization platform

· Unique T cell signaling tweaking strategy and TME-specific promoter to broaden tumor cell coverage while ensuring safety. LEARN MORE

* MSE-T

T cell functional enhancement platform

MSE-T

T cell functional enhancement platform

· Library consisting of hundreds of motifs for T cell functional enhancement. LEARN MORE

* IDENTIFIER

Antigen/Antibody/TCR discovery platform

IDENTIFIER

Antigen/Antibody/TCR discovery platform

· Large tumor-specific TCR library for multiple high-frequency HLA haplotypes.

· Fast screening / optimization. LEARN MORE

Global strategy to serve patients worldwide with scalable GMP

production capability and broad clinical network

* America Stanford University School of Medicine

France Gustave Roussy Cancer Campus

Germany Helmholtz Zentrum München-German Research Center

China Sun Yat-sen University Cancer Center

Singapore The Agency for Science, Technology and Research, Singapore

* Australia QIMR Berghofer Medical Research Institute

LEARN MORE

Exclusive Partnership with Public Agencies to pursue breakthrough in development

Accelerate R&D progress with cooperative of Top scientific research institutions

Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.

Collaboration targets multiple indications . exclusive collaboration in NPC.

13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government

Abundant clinical resources around the world

Clinical trials have been initiated at 8 medical centers in China

Clinical trials of NCCS are already ongoing in Singapore

Accelerate R&D progress with cooperative of Top scientific research institutions

Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.

Collaboration targets multiple indications . exclusive collaboration in NPC.

13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government

Abundant clinical resources around the world

Clinical trials have been initiated at 8 medical centers in China

Clinical trials of NCCS are already ongoing in Singapore

Accelerate R&D progress with cooperative of Top scientific research institutions

Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.

Collaboration targets multiple indications . exclusive collaboration in NPC.

13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government

Abundant clinical resources around the world

Clinical trials have been initiated at 8 medical centers in China

Clinical trials of NCCS are already ongoing in Singapore

Accelerate R&D progress with cooperative of Top scientific research institutions

Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.

Collaboration targets multiple indications . exclusive collaboration in NPC.

13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government

Abundant clinical resources around the world

Clinical trials have been initiated at 8 medical centers in China

Clinical trials of NCCS are already ongoing in Singapore

Accelerate R&D progress with cooperative of Top scientific research institutions

Sun Yat-sen University Cancer Center: The company is the sole collaborator with SYSUCC for registration of somatic cell therapy clinical trial center in National Health Commission of the PRC.

Collaboration targets multiple indications . exclusive collaboration in NPC.

13th Singapore Guangdong Collaboration Council (Jun 2023) – Agreement to set up the Translation Medicine Centre with Guangzhou District Government

Dual site strategy

Dual site strategy with dual R&D and GMP Facilities to address Global needs